Efficacy and safety of tacrolimus or infliximab therapy in children and young adults with acute severe colitis, August 2023 JPGN

Efficacy and safety of tacrolimus or infliximab therapy in children and young adults with acute severe colitis, August 2023 JPGN

Key:

Complete
Failed
Available
Locked
CME Requirements and Learning Objectives: Efficacy and safety of tacrolimus or infliximab therapy in children and young adults with acute severe colitis, August 2023 JPGN
Open to download resource.
Open to download resource.
You must register to access.
Efficacy and safety of tacrolimus or infliximab therapy in children and young adults with acute severe colitis, August 2023 JPGN
Open to download resource.
Open to download resource.
You must register to access.
Post-Test: Efficacy and safety of tacrolimus or infliximab therapy in children and young adults with acute severe colitis, August 2023 JPGN
3 Questions  |  Unlimited attempts  |  2/3 points to pass
3 Questions  |  Unlimited attempts  |  2/3 points to pass
You must register to access.
Post-Webinar Evaluation: Efficacy and safety of tacrolimus or infliximab therapy in children and young adults with acute severe colitis, August 2023 JPGN
14 Questions
14 Questions Post-Webinar Evaluation: Efficacy and safety of tacrolimus or infliximab therapy in children and young adults with acute severe colitis, August 2023 JPGN
You must register to access.
Certificate: Efficacy and safety of tacrolimus or infliximab therapy in children and young adults with acute severe colitis, August 2023 JPGN
1.00 credit  |  Certificate available
1.00 credit  |  Certificate available
You must register to access.